


Depo-Provera and Meningiomas: Consensus Recommendations From Europe

Study links progestin use to increased meningioma risk, with discontinuation often leading to tumor regression, highlighting the need for monitoring

SANTA BARBARA, CA, UNITED STATES, March 21, 2025

/EINPresswire.com/ -- "A combined effort was initiated between Neurosurgical, Gynaecological and Endocrinological societies of Belgium to gather relevant information regarding sex hormone therapies and meningioma. After complete literature review, consensual recommendations were established," states Sebastien Froelich, Department of Neurosurgery, Leuven, Belgium.

What did Dr. Sebastien Froelich report in the 2025 article "Recommendations on the management of meningioma and sex hormone therapy: The results of a collaborative effort between neurosurgical, endocrine and gynecological societies" published in *Brain and Spine* 5(2025) 104154?:



Greg Vigna, MD

“The causal link between Progestin use and the risk of meningioma was first doubted but is now acknowledged because of its specific features: the dose-effect relationship, the reduction of risk after treatment discontinuation, the specificity of the tumor location, and the specificity of the somatic mutational landscape of Progestin-associated meningiomas.

“

Depo-Provera has been a bad drug for a long time. There have always been safer medications for contraception than the shot.”

Greg Vigna, MD

For patients on progestin therapy, healthcare providers should implement a monitoring plan that includes yearly physical exams, especially focusing on neurological and ophthalmological status and imaging studies, particularly

for individuals with a higher risk of developing meningiomas.

In case of meningioma, all preparations containing progestin must be stopped. Studies have shown regression or stabilization of meningiomas upon discontinuation of progestin treatment.

Discontinuing progestin is an appropriate management strategy, especially when surgery is not urgently required.

Another feature of Progestin-associated Meningiomas is their location. They appear to be primarily located at the skull base, in the anterior and middle cranial fossae, in contact with the body and the wings of the sphenoid bone.

Additionally, Progestin-associated meningiomas seem to exhibit a higher frequency of somatic PIK3CA mutations, suggesting a hormone- induced mutational shift promoting growth and increasing cell invasion."

Read Dr. Froelich's article:

<https://www.sciencedirect.com/science/article/pii/S2772529424014103>

[Dr. Greg Vigna](#) concludes, "Depo-Provera has been a bad drug for a long time. There have always been safer medications for contraception than the shot."

Dr. Vigna is a California and Washington DC lawyer and is co-counsel with the [Ben Martin Law Group](#), a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent neurological injuries across the country on a non-exclusive basis.

[Click here](#) for a free book on Vaginal Mesh Pain, Birth Injury, and Decubitus Ulcers.

Greg Vigna, MD, JD

Vigna Law Group

+1 8178099023

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796036720>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.